CN101176716A - Sunitinib sustained-release implantation agent for curing entity tumour - Google Patents

Abstract

The invention relates to a sunitinib sustained-release implant capability for curing solid tumors, such as lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer, colon cancer and rectum cancer. The invention is characterized in that: the sustained-release implant comprises sunitinib, sustained-release excipient and a certain amount of sustained-release regulator; the sustained-release excipient is mainly one or the combination of the copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co-propyl phosphate); the sunitinib can be released slowly into part of the tumor during the degradation and adsorption, significantly reducing the systemic toxicity and sustaining the effective medicine concentration simultaneously. The invention has the advantages that: the systemic toxicity of sunitinib can be significantly reduced; the effective medicine concentration can be improved selectively at part of the tumor; the invention can be applied to the prevention of tumor recurrence after operation and chemotherapy and combined therapy of various solid tumors and metastatic tumors that are not suitable for operation.

Description

A kind of sunitinib sustained-release implantation agent for the treatment of entity tumor

(1) technical field

The present invention relates to a kind of sunitinib sustained-release implantation agent for the treatment of entity tumor, belong to technical field of pharmaceuticals.

(2) background technology

In the decades in past, though obtained bigger progress about the research of cancer, its mortality rate still occupies the prostatitis of the various common causes of the death.Up-to-date data show that China had 3,000,000 people to die from cancer in 2006.Because be subjected to the influence of environmental pollution and Bad Eating Habit, the sickness rate of cancer rises year by year and is rejuvenation trend.Have data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Estimate that the year two thousand twenty China will have 4,000,000 people to die from cancer every year.Therefore, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.

Sutent (Sunitinib, Sutent) be a class optionally targeting at one of original new drug in the newtype drug of multiple receptor tyrosine kinase.It comes antitumor by blocking required blood of tumor growth and nutrient substance supply and these two kinds of mechanism of action of direct aggression tumor cell, so its clinical advantage is conspicuous.It may represent the appearance of new round targeted therapies.Yet this effect that will be used for the treatment of other tumor separately is unclear.Though unite some tumors may be had certain effect by tool, limited its clinical practice by the caused whole body toxic and side effects of conventional route administration with other anticarcinogen.

(3) summary of the invention

Based on above examination to prior art, the present invention compares other tumor, found that Sutent has comparatively significantly action effect to multiple entity tumor.Yet conventional method is difficult to bring into play its anti-tumor effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.

The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of entity tumor, not only effect is obvious, and its general toxicity obviously alleviates.

The present invention treats the sustained-release implant of entity tumor, it is characterized in that this sustained-release implant contains the Sutent of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:

(1) Sutent 0.1%-40%

(2) slow-release auxiliary material 60%-99%

(3) slow release regulator 0-15%

Wherein Sutent can be its various salt, preferred salt hydrochlorate.The percentage by weight of Sutent in sustained-release implant decide because of specifically needing, 1% to 30% serving as preferably, with 5%-20% for most preferably.

Decanedioic acid (SA) copolymer), a kind of or its combination among poly-(L-lactide-co-etherophosphoric acid) (p (LAEG-EOP)), poly-(L-lactide-co-phosphoric acid propyl ester) (p (DAPG-EOP)) slow-release auxiliary material of the present invention mainly is selected from the copolymer (PLGA), polifeprosan of polylactic acid (PLA), glycolic and hydroxyacetic acid (to carboxy phenyl propane (p-CPP):.

Wherein the molecular weight peak value of polylactic acid (PLA) is 5000-15000,10000-20000,20000-35000 or 30000-50000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.

The molecular weight peak value of the copolymer of glycolic and hydroxyacetic acid (PLGA) is 5000-15000,15000-35000,35000-45000 or 45000-80000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.The percentage by weight of glycolic and hydroxyacetic acid is 90: 10,80: 20, and 70: 30,60: 40,50: 50 or 40: 60; Wherein with 80: 20,70: 30,60: 40, be preferred at 50: 50, with 60: 40 and 50: 50 for most preferably.

Polifeprosan (to carboxy phenyl propane (p-CPP): the percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) decanedioic acid (SA) copolymer) is 10: 90,20: 80, and 30: 70,40: 60,50: 50 or 60: 40; Wherein with 80: 20,70: 30,60: 40, be preferred at 50: 50, with 60: 40 and 50: 50 for most preferably.

The molecular weight peak value of poly-(L-lactide-co-etherophosphoric acid) is 5000-15000,10000-20000,20000-35000 or 30000-50000, serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.

In " slow-release auxiliary material complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor), slow-release auxiliary material is had a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some slow-release auxiliary material.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above slow-release auxiliary material has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned slow-release auxiliary material, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.

The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.Serve as preferred wherein with mannitol, sorbitol.

Characteristics of the present invention are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other slow-release auxiliary material.The slow-release auxiliary material of adding is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.

Slow-release auxiliary material also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned slow-release auxiliary material is applicable to the compositions that contains or do not contain additive

The consumption of sustained-release implant depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 0.1-500 milligram/patient, is ideal with 10-300 milligram/patient, with 20-200 milligram/patient for the most desirable.

The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to, injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc., wherein implant is mainly sustained-release implant, controlled release implant or slowbreak implant; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and apperance; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferably for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant and sustained-release implant as selecting for use.

Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of compositions can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.

Each component and the weight percentage in compositions thereof are preferred one of following in the sustained-release implant:

(A) polylactic acid of the Sutent of 1%-5% and 95%-99%;

(B) polylactic acid of the Sutent of 5%-10% and 90%-95%;

(C) polylactic acid of the Sutent of 10%-15% and 85%-90%;

(D) polylactic acid of the Sutent of 15%-25% and 75%-85%;

(E) polylactic acid of the Sutent of 25%-40% and 60%-75%;

(F) copolymer of the glycolic of the Sutent of 1%-10% and 90%-99% and hydroxyacetic acid;

(G) copolymer of the glycolic of the Sutent of 10%-20% and 80%-90% and hydroxyacetic acid;

(H) copolymer of the glycolic of the Sutent of 20%-30% and 70%-80% and hydroxyacetic acid;

(I) copolymer of the glycolic of the Sutent of 30%-40% and 60%-70% and hydroxyacetic acid;

(J) polifeprosan of the Sutent of 5%-15% and 85%-95%;

(K) polifeprosan of the Sutent of 15%-35% and 65%-85%;

(L) 5% Sutent and 95% poly-(L-lactide-co-etherophosphoric acid);

(M) 10% Sutent and 90% poly-(L-lactide-co-etherophosphoric acid);

(N) 20% Sutent and 80% poly-(L-lactide-co-etherophosphoric acid);

(O) 30% Sutent and 70% poly-(L-lactide-co-etherophosphoric acid);

(P) 5% Sutent and 95% poly-(L-lactide-co-phosphoric acid propyl ester);

(Q) 10% Sutent and 90% poly-(L-lactide-co-phosphoric acid propyl ester);

(R) 20% Sutent and 80% poly-(L-lactide-co-phosphoric acid propyl ester);

(S) 30% Sutent and 70% poly-(L-lactide-co-phosphoric acid propyl ester).

Each component and the weight percentage in compositions thereof are one of further preferred following in the sustained-release implant:

(A) mannitol of the polylactic acid of the Sutent of 1%-5% and 85%-98% and 0.5%-15%;

(B) sorbitol of the polylactic acid of the Sutent of 5%-10% and 90%-95% and 0.5%-10%;

(C) sodium chloride of the polylactic acid of the Sutent of 10%-15% and 85%-90% and 0.5%-10%;

(D) mannitol of the polylactic acid of the Sutent of 15%-25% and 75%-85% and 0.25%-5%;

(E) sorbitol of the polylactic acid 0.1%-8% of the Sutent of 25%-40% and 60%-75%;

(F) mannitol of the copolymer of the glycolic of the Sutent of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;

(G) sorbitol of the copolymer of the glycolic of the Sutent of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;

(H) sodium chloride of the copolymer of the glycolic of the Sutent of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;

(I) mannitol of the copolymer of the glycolic of the Sutent of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;

(J) mannitol of the polifeprosan of the Sutent of 5%-15% and 85%-95% and 1%-5%;

(K) mannitol of the polifeprosan of the Sutent of 15%-35% and 65%-85% and 0.25%-7.5%;

(L) 5% Sutent and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;

(M) 10% Sutent and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(N) 20% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(O) 30% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(P) 5% Sutent and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;

(Q) 10% Sutent and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(R) 20% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(S) 30% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.

Sustained-release implant is used for the treatment of entity tumor, comprise the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and come from gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes, former or cancer, sarcoma or the carcinosarcoma of secondary.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.

Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Because anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.

When used the part, said composition can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.

Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.

Anti-cancer composition of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.

Test one, Sutent are to the inhibitory action of growth of tumour cell.

Be the inhibitory action of checking Sutent to other growth of tumour cell, this test is added to Sutent (15ug/ml) in 24 hours the various tumor cells of In vitro culture (table 1), continue to cultivate after 48 hours the counting cells sum and calculates its suppression ratio to growth of tumour cell (%).

The suppression ratio of growth of tumour cell (%)=((cellular control unit is counted the test group cell number)/cellular control unit number) * 100%

Table 1

Tumor cell	Suppression ratio (%)
		Hepatocarcinoma	74
Pulmonary carcinoma	68
		The esophageal carcinoma	50
Gastric cancer	68
		Breast carcinoma	72
Cancer of pancreas	60
		Thyroid carcinoma	68
Nasopharyngeal carcinoma	76
		Ovarian cancer	60
Carcinoma of endometrium	70
		Cervical cancer	72
Renal carcinoma	78
		Carcinoma of prostate	70
Bladder cancer	76
		Colon cancer	72
Rectal cancer	50
		Skin carcinoma	58
Lymphoma	72
		Carcinoma of testis	62

The result of test one shows that compare with matched group, Sutent all has obvious inhibitory action (P＜0.05) to the examination growth of tumor, and is wherein right.This is unexpected finds to constitute major technique feature of the present invention, for the treatment of entity tumor provides new selection.

The sustained-release implant that contains Sutent can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing of implanting.

The preparation method of sustained-release implant of the present invention is as follows:

1, the slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.

2, adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement.

3, remove organic solvent.Vacuum drying or cold drying all can.

4, dried solid composite is made different shape as required.

5, ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.

(4) specific embodiment

Embodiment one,

The slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) of (95mg) of will weighing is put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 5 milligrams of Sutents, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 5% Sutent.The drug release time of this sustained-release implant in external normal saline is 24-28 days, is 25-30 days at the subcutaneous drug release time of mice.

Embodiment two

Make sustained-release implant by embodiment one described method, but contained anticancer effective component is one of following:

(A) 1% Sutent and and 99% polylactic acid;

(B) 5% Sutent and and 95% polylactic acid;

(C) 10% Sutent and 90% polylactic acid;

(D) 15% Sutent and 85% polylactic acid;

(E) 20% Sutent and 80% polylactic acid.

Embodiment three

(molecular weight is the PLGA of 15000-25000 to the slow-release auxiliary material of (90mg) of will weighing, 50: 50) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add the 10mg Sutent, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% Sutent.The drug release time of this sustained-release implant in external normal saline is 25-32 days, is 25-34 days at the subcutaneous drug release time of mice.

Embodiment four

Make sustained-release implant by embodiment three described methods, contained anticancer effective component that different is is one of following:

(1) copolymer of the glycolic of the Sutent of 1%-10% and 90%-99% and hydroxyacetic acid;

(2) copolymer of the glycolic of the Sutent of 10%-20% and 80%-90% and hydroxyacetic acid;

(3) copolymer of the glycolic of the Sutent of 20%-30% and 70%-80% and hydroxyacetic acid;

(4) copolymer of the glycolic of the Sutent of 30%-40% and 60%-70% and hydroxyacetic acid;

The copolymer of (5) 5% Sutent and 95% glycolic and hydroxyacetic acid;

The copolymer of (6) 10% Sutent and 90% glycolic and hydroxyacetic acid;

The copolymer of (7) 20% Sutent and 80% glycolic and hydroxyacetic acid;

The copolymer of (8) 30% Sutent and 70% glycolic and hydroxyacetic acid.

Embodiment five

(molecular weight is the PLGA of 20000-40000 to the slow-release auxiliary material of (85mg) of will weighing, 75: 25) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add 10mg Sutent and 5mg mannitol, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% Sutent.The drug release time of this sustained-release implant in external normal saline is 26-28 days, is 26-28 days at the subcutaneous drug release time of mice.

Embodiment six

Make sustained-release implant by embodiment five described methods, contained anticancer effective component that different is is one of following:

(1) mannitol of the copolymer of the glycolic of the Sutent of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;

(2) sorbitol of the copolymer of the glycolic of the Sutent of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;

(3) sodium chloride of the copolymer of the glycolic of the Sutent of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;

(4) mannitol of the copolymer of the glycolic of the Sutent of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;

The copolymer of (5) 5% Sutent and 92% glycolic and hydroxyacetic acid and 2% sodium chloride;

The copolymer of (6) 10% Sutent and 85% glycolic and hydroxyacetic acid and 5% mannitol;

The copolymer of (7) 20% Sutent and 75% glycolic and hydroxyacetic acid and 5% mannitol;

The copolymer of (8) 30% Sutent and 75% glycolic and hydroxyacetic acid and 5% mannitol.

Embodiment seven

95mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 50: 50) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 5mg Sutent, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 5% sunitinib sustained-release implantation agent.The drug release time of this sustained-release implant in external normal saline is 12-16 days, is 10-14 days at the subcutaneous drug release time of mice.

Embodiment eight

Make sustained-release implant by embodiment seven described methods, that contained anticancer effective component is is one of following but different is:

(1) polifeprosan of the Sutent of 1%-15% and 85%-95%;

(2) polifeprosan of the Sutent of 15%-35% and 65%-85%;

(3) 5% Sutent and 95% polifeprosan;

(4) 10% Sutent and 90% polifeprosan;

(5) 15% Sutent and the polifeprosan of 85%-95%;

(6) 20% Sutent and 80% polifeprosan.

Embodiment nine

90mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 30: 70) and 5mg sodium chloride are put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 5mg Sutent, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 5% sunitinib sustained-release implantation agent.The drug release time of this sustained-release implant in external normal saline is 8-14 days, is 10-15 days at the subcutaneous drug release time of mice.

Embodiment ten

Make sustained-release implant by embodiment ten described methods, that contained anticancer effective component is is one of following but different is:

(1) mannitol of the polifeprosan of the Sutent of 5%-15% and 85%-95% and 1%-5%; Or

(2) mannitol of the polifeprosan of the Sutent of 15%-35% and 65%-85% and 0.25%-7.5%.

Embodiment 11

85mg slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) and 10mg mannitol are put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 5 milligrams of Sutents, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 5% Sutent.The drug release time of this sustained-release implant in external normal saline is 22-24 days, is 24-28 days at the subcutaneous drug release time of mice.

Embodiment 12

Make sustained-release implant by embodiment 11 described methods, used slow-release auxiliary material is selected from one of following or its combination:

(A) 1% Sutent and and 95% polylactic acid and 4% mannitol;

(B) 5% Sutent and and 93% polylactic acid and 2% mannitol;

(C) 10% Sutent and 85% polylactic acid and 5% mannitol;

(D) 15% Sutent and 82% polylactic acid and 3% sodium chloride;

(E) 20% Sutent and 78% polylactic acid and 2% sodium chloride.

Embodiment 13

Make sustained-release implant by embodiment 1 to 11 described method, used slow-release auxiliary material is selected from one of following or its combination:

A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;

B) molecular weight is the polyglycolic acid of 5000-15000,15000-35000,35000-45000 or 45000-80000 and the copolymer of hydroxyacetic acid (PLGA);

C) polifeprosan is (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) copolymer), be 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to the percentage by weight of carboxy phenyl propane (p-CPP) and decanedioic acid (SA);

On the basis of above-mentioned slow release, the present invention finds that further body is implanted into Sutent other entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer, rectal cancer, ovarian cancer, skin carcinoma, lymphoma, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate are also had good therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.Following in vivo test is used for explanation but not limitation of the present invention.

Embodiment 14

With 70,80,90 and 95mg molecular weight peak value be that the p (LAEG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg Sutent respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% Sutent again.The drug release time of this slow releasing agent in external normal saline is 28-36 days, is about 28-38 days at the subcutaneous drug release time of mice.

Embodiment 15

The method step that is processed into sustained-release implant is identical with embodiment 14, but the molecular weight peak value of different is p (LAEG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:

(1) 1%-5% Sutent;

(2) 5%-10% Sutent;

(3) 10%-20% Sutent;

(4) 20%-40% Sutent;

The sodium chloride of (5) 5% Sutent and 92% p (LAEG-EOP) and 2%;

The mannitol of (6) 10% Sutent and 85% p (LAEG-EOP) and 5%;

The mannitol of (7) 20% Sutent and 75% p (LAEG-EOP) and 5%;

The mannitol of (8) 30% Sutent and 75% p (LAEG-EOP) and 5%.

Embodiment 16

With 70,80,90 and 95mg molecular weight peak value be that the p (DAPG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg Sutent respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% Sutent again.The drug release time of this slow releasing agent in external normal saline is 36-42 days, is about 38-44 days at the subcutaneous drug release time of mice.

Embodiment 17

The method step that is processed into sustained-release implant is identical with embodiment 16, but the molecular weight peak value of different is p (DAPG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:

(1) 1%-5% Sutent;

(2) 5%-10% Sutent;

(3) 10%-20% Sutent;

(4) 20%-40% Sutent;

The sodium chloride of (5) 5% Sutent and 92% p (DAPG-EOP) and 2%;

The mannitol of (6) 10% Sutent and 85% p (DAPG-EOP) and 5%;

The mannitol of (7) 20% Sutent and 75% p (DAPG-EOP) and 5%;

The mannitol of (8) 30% Sutent and 75% p (DAPG-EOP) and 5%.

Embodiment 18, tumor are implanted into the inhibitory action of Sutent to entity tumor

Tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, when tumor growth during to 1.0cm left and right sides diameter (inoculation back the 8th day), animal is divided into 7 groups at random, 5 every group.Be normal saline group, Sutent lumbar injection group (hereinafter to be referred as Sutent abdominal cavity group), Sutent local injection group (being called for short the Sutent partial groups), high molecular polymer group (being called for short high poly-group), sunitinib sustained-release implantation agent group with (5% group, 10% group of the made sustained-release implant of embodiment four, with 20% group, be called for short implant 5%, implant 10%, implant 20%).With 70% alcohol disinfecting tumor surface skin, selection is apart from tumor lower edge 1cm place, cut off the long otch of 1mm, with puncture needle with in the Sutent implant implantation tumour tissue, not pastille high molecular polymer, Sutent implant 5%, Sutent implant 10%, Sutent implant 20%.Sew up the incision and prevent that implant from spilling.6 weeks were put to death animals after the implant embedding with vernier caliper measurement tumor size in per 3 days, and the back of weighing is complete peels off tumor and claim tumor heavy.Calculate tumor control rate %, DAS.ver1.0 pharmacology software is done statistical procedures.

Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%

Embodiment 19, tumor are implanted into the tumor-inhibiting action of Sutent spit of fland sustained-release implant to mice lung cancer

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent according to embodiment 18 described methods and step to mice lung cancer.Used implant adjuvant is PLGA (molecular weight is 15000-30000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50), is derived from embodiment four.The Sutent implant of this experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 50%, 62%, 76%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments: tumor control rate is respectively 56%, 68%, 80%, compares with the local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and Sutent local injection group and normal saline group comparison of tumor suppression ratio are 10% and 12%, and repeated experiments: tumor control rate is 12% and 13%.The tumour inhibiting rate of Sutent implant obviously surpasses Sutent lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 20 tumors are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to mouse breast cancer

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent to mouse breast cancer according to embodiment 18 described methods and step, used implant is from embodiment one.Experimental result shows that the tumor control rate of 1%, 10% and 25% Sutent implant is respectively 42%, 62%, 74%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 50%, 66%, 76%, compares with Sutent local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 10% and 14%, and repeated experiments: tumor control rate is 10% and 10%.The tumour inhibiting rate of Sutent implant obviously surpasses Sutent lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 21, tumor are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mouse ovarian cancer

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent according to embodiment 18 described methods and step to the mouse ovarian cancer, used implant is 5%, 10% and 20% polifeprosan (percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) is 50: 50), from embodiment eight.The Sutent implant of experimental result proof various dose is implanted in the mouse ovarian cancer and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 48%, 70%, 78%, compares with Sutent local injection group, and low dose group P value equals 0.001, and middle and high dosage group P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 40%, 66%, 74%, compares with Sutent local injection group, and low dose group P value is less than 0.05, and middle and high dosage group P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and Sutent local injection group and normal saline group comparison of tumor suppression ratio are 18% and 12%, and repeated experiments: tumor control rate is 15% and 16%.The tumour inhibiting rate of Sutent implant obviously surpasses Sutent lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 22 tumors are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mice esophageal carcinoma

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mice esophageal carcinoma according to embodiment 18 described methods and step, used implant is selected from embodiment six.The Sutent implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 48%, 66%, 74%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments finds that tumor control rate is respectively 46%, 72%, 80%, compares with Sutent local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 10% and 16%, and repeated experiments shows that tumor control rate is 14% and 10%.The tumour inhibiting rate of Sutent implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 23, tumor are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to mouse pancreas cancer

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent to mouse pancreas cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of Sutent in sustained-release implant be 2.5%, 7.5% and the Sutent implant of 12.5%. experimental result proof various dose implant in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 40%, 56%, 78%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 48%, 62%, 76%, compares with Sutent local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 14%.Repeated experiments finds that tumor control rate is 10% and 14%.The tumour inhibiting rate of Sutent implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 24, tumor are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mice rectal cancer

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mice rectal cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of Sutent in sustained-release implant is the Sutent implant of 7.5%, 15% and 25%. experimental results proof various dose, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 50%, 72%, 89%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 50%, 72%, 84%, compares with Sutent local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 18%.Repeated experiments finds that tumor control rate is 12% and 10%.The tumour inhibiting rate of Sutent implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 25, tumor are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mice carcinoma of prostate

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent to the mice carcinoma of prostate according to embodiment 18 described methods and step, used implant adjuvant is p (LAEG-EOP) (molecular weight is 10000-25000).The content of Sutent in sustained-release implant is 5%, 10% and 20% (from embodiment 14). the Sutent implant of experimental result proof various dose is implanted in the nude mice model human prostata cancer entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 52%, 72%, 84%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 42%, 68%, 78%, compares with Sutent local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 18%.Repeated experiments finds that tumor control rate is 12% and 14%.The tumour inhibiting rate of Sutent implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

Embodiment 26, tumor are implanted into the tumor-inhibiting action of sunitinib sustained-release implantation agent to rat liver cancer

Check the tumor-inhibiting action of sunitinib sustained-release implantation agent to rat liver cancer according to embodiment 18 described methods and step, used implant adjuvant is p (DAPG-EOP) (molecular weight is 10000-25000).The content of Sutent in sustained-release implant is 5%, 10% and 20% (from embodiment 16). the content of Sutent in sustained-release implant is the Sutent implant of 7.5%, 15% and 25%. experimental results proof various dose, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Sutent implant tumor control rate is respectively 52%, 74%, 82%, compares with Sutent local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 52%, 66%, 80%, compares with Sutent local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Sutent lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 16% and 12%.Repeated experiments finds that tumor control rate is 8% and 10%.The tumour inhibiting rate of Sutent implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.

In addition, tumor is implanted into sunitinib sustained-release implantation agent other entity tumors such as gastric cancer, bladder cancer, carcinoma of testis, colon cancer, carcinoma of endometrium, lymphoma, the cerebral tumor, cervical cancer, renal carcinoma is also had good therapeutical effect, and its effect obviously surpasses Sutent lumbar injection group and local injection group.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.

Claims (10)

1. a sunitinib sustained-release implantation agent for the treatment of entity tumor is characterized in that this sustained-release implant contains the Sutent of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, wherein,

The percentage by weight of Sutent in sustained-release implant is 0.1%-40%;

Slow-release auxiliary material is selected from a kind of or its combination in the copolymer, polifeprosan of polylactic acid, polyglycolic acid and hydroxyacetic acid, poly-(L-lactide-co-etherophosphoric acid), poly-(the L-lactide-co-phosphoric acid propyl ester);

The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin; Its percentage by weight in sustained-release implant is 0-15%.

2. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:

(A) 1% Sutent and and 99% polylactic acid;

(B) 5% Sutent and and 95% polylactic acid;

(C) 10% Sutent and 90% polylactic acid;

(D) 15% Sutent and 85% polylactic acid;

(E) 20% Sutent and 80% polylactic acid;

(F) 5% Sutent and 95% glycolic and the copolymer of hydroxyacetic acid;

(G) 10% Sutent and 90% glycolic and the copolymer of hydroxyacetic acid;

(H) 20% Sutent and 80% glycolic and the copolymer of hydroxyacetic acid;

(I) 30% Sutent and 70% glycolic and the copolymer of hydroxyacetic acid;

(J) 5% Sutent and 95% polifeprosan;

(K) 15% Sutent and 85% polifeprosan;

(L) 5% Sutent and 95% poly-(L-lactide-co-etherophosphoric acid);

(M) 10% Sutent and 90% poly-(L-lactide-co-etherophosphoric acid);

(N) 20% Sutent and 80% poly-(L-lactide-co-etherophosphoric acid);

(O) 30% Sutent and 70% poly-(L-lactide-co-etherophosphoric acid);

(P) 5% Sutent and 95% poly-(L-lactide-co-phosphoric acid propyl ester);

(Q) 10% Sutent and 90% poly-(L-lactide-co-phosphoric acid propyl ester);

(R) 20% Sutent and 80% poly-(L-lactide-co-phosphoric acid propyl ester);

(S) 30% Sutent and 70% poly-(L-lactide-co-phosphoric acid propyl ester).

3. the sustained-release implant according to claim 1 is characterized in that the slow release regulator of this sustained-release implant is selected from xylitol, oligosaccharide, chitin, potassium chloride, sodium chloride, mannitol, sorbitol, hyaluronic acid, collagen protein or chrondroitin.

4. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:

(A) 1% Sutent and and 95% polylactic acid and 4% mannitol;

(B) 5% Sutent and and 93% polylactic acid and 2% mannitol;

(C) 10% Sutent and 85% polylactic acid and 5% mannitol;

(D) 15% Sutent and 82% polylactic acid and 3% sodium chloride;

(E) 20% Sutent and 78% polylactic acid and 2% sodium chloride;

(F) 5% Sutent and 92% glycolic and the copolymer of hydroxyacetic acid and 2% sodium chloride;

(G) 10% Sutent and 85% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;

(H) 20% Sutent and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;

(I) 30% Sutent and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;

(J) 5% Sutent and 92.5% polifeprosan and 2.5% mannitol;

(K) 15% Sutent and 75% polifeprosan and 10% mannitol;

(L) 5% Sutent and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;

(M) 10% Sutent and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(N) 20% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(O) 30% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(P) 5% Sutent and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;

(Q) 10% Sutent and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(R) 20% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;

(S) 30% Sutent and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.

5. according to the described anti-cancer sustained-released implantation agent of claim 1-4, the molecular weight peak value that it is characterized in that polylactic acid is 5000-15000,10000-20000,20000-35000 or 30000-50000.

6. according to the described anti-cancer sustained-released implantation agent of claim 1-4, the molecular weight peak value that it is characterized in that the copolymer of glycolic and hydroxyacetic acid is 5000-15000,15000-35000,35000-45000 or 45000-80000.

7. according to the described anti-cancer sustained-released implantation agent of claim 1-4, it is characterized in that in the copolymer of glycolic and hydroxyacetic acid that the percentage by weight of glycolic and hydroxyacetic acid is 90: 10,80: 20,70: 30,60: 40,50: 50 or 40: 60.

8. according to the described anti-cancer sustained-released implantation agent of claim 1-4, it is characterized in that the percentage by weight to carboxy phenyl propane and decanedioic acid is 10: 90 in the polifeprosan (to carboxy phenyl propane-decanedioic acid copolymer), 20: 80,30: 70,40: 60,50: 50 or 60: 40.

9. the described sustained-release implant of claim 1-3 is characterized in that this sustained-release implant is in the tumor or the slow releasing injection and the solid sustained-release implant of all injections of tumor or placement.

10. the sustained-release implant according to claim 1 is characterized in that described sustained-release implant is used for the preparation treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and originate from gallbladder, the oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, former or the cancer of secondary of eyes, the pharmaceutical preparation of sarcoma or carcinosarcoma.